[ad_1]
The trial will evaluate the safety and efficacy of the anticoagulant, administered in different doses, to improve the course of the disease.
ai 14 Italian centers involved In the study, the medication will be provided free of charge. L ‘enoxaparin sodium is a low molecular weight heparin with ahigh antithrombotic action what makes it, to date, one of the most widely used anticoagulants for the prevention and treatment of venous and arterial thromboembolism in subjects undergoing surgery or bedridden. The 300 patients entered in the trial will receive biosimilar enoxaparin subcutaneously.
The study will be coordinated by Pierluigi Viale, Professor of Infectious Diseases at the University of Bologna and director of the Operational Unit for Infectious Diseases of the Sant’Orsola-Malpighi Hospital. Changes in coagulation and thrombotic complications In patients with Covid-19, experts point out that they play an important role in terms of incidence and clinical relevance, representing one of the most important variables associated with mortality.
In January theWHO had recommended preventing venous thromboembolism in subjects infected with Sars-Cov2 by resorting to subcutaneous administration of heparin, preferably with low molecular weight. In the light of scientific evidence collected so far and the encouraging results from studies conducted in China, both in vitro and in patients, the idea of promoting an experiment also in Italy using, for therapeutic purposes, a medium-high dose of the drug.
“Other important piece of our therapeutic arsenal against the virus enters the clinical trial phase, which is more necessary than ever to better understand its function and applicability, “Viale explained.” We need, he continued, to acquire evidence quickly, and therefore we must work within clinical pathways, associating our intuitions with the necessary methodological rigor “.
[ad_2]
